Australia markets closed

SNY Jan 2024 50.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.30000.0000 (0.00%)
At close: 10:30AM EDT
Full screen
Previous close3.3000
Open3.6000
Bid2.5000
Ask4.3000
Strike50.00
Expiry date2024-01-19
Day's range3.3000 - 3.6000
Contract rangeN/A
Volume4
Open interest210
  • Motley Fool

    Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?

    Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.

  • Motley Fool

    Is Sanofi Stock a Buy Now?

    French pharmaceutical giant Sanofi (NASDAQ: SNY) has long been a leader in the market for insulin. First, Sanofi was forced to decrease the price of its most prescribed insulin product after its only two real competitors in this area did something similar. Second, Sanofi announced the acquisition of Provention Bio, a biotech focusing on developing medicines to delay or prevent the onset of autoimmune diseases, such as Type 1a diabetes.

  • Zacks

    Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

    Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.